Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria

Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria

Aim: to assess the economic outcomes of using ceftazidime + avibactam (compared with the recommended treatments) in adult patients with sepsis caused by carbapenem-resistant enterobacteria.Methods. The economic assessment was made using the cost-effectiveness analysis and budget impact analysis. The...

Full description

Saved in:

Bibliographic Details
Main Authors:	S. V. Nedogoda, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2019-07-01
Series:	Фармакоэкономика
Subjects:	sepsis carbapenem-resistant enterobacteria bacteria with multiple resistance ceftazidime + avibactam budget impact analysis cost-effectiveness analysis
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/289
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comparison of meropenem-vaborbactam with ceftazidime-avibactam in the treatment of carbapenem-resistant Enterobacterales infections
by: Luca Mezzadri, et al.
Published: (2024-12-01)

Ceftazidime-avibactam resistance determination in carbapenem-resistant Klebsiella pneumoniae infections before its use in practice
by: Oya Özlem Eren-Kutsoylu, et al.
Published: (2024-07-01)

IN VITRO ACTIVITY OF CEFTAZIDIME-AVIBACTAM AND COLISTIN AGAINST CARBAPENEM-RESISTANT PSEUDOMONAS AERUGINOSA CLINICAL ISOLATES
by: Tuğrul Hoşbul, et al.
Published: (2022-07-01)

Efficacy of ceftazidime-avibactam with or without polymyxin for carbapenem-resistant Klebsiella pneumoniae infections after initial treatment with polymyxin
by: Jingli Lu, et al.
Published: (2025-01-01)

Aztreonam Acts as a Synergist for Ceftazidime/Avibactam Against Carbapenem-Resistant Enterobacteriaceae (CRE) of Various Carbapenemase Phenotypes in Southwestern China
by: Ruan X, et al.
Published: (2025-05-01)

Ceftazidime/avibactam as a possible treatment option for carbapenem-resistant Enterobacterales infections
by: Ana Kaftandzieva, et al.
Published: (2025-12-01)

Clinical Eﬃcacy of Ceftazidime-Avibactam in the Treatment of Infections Caused by Carbapenem–Resistant Gram-Negative Bacteria
by: S. V. Yakovlev
Published: (2021-10-01)

Mortality and clinical outcomes of ceftazidime/avibactam vs best available therapy in treating carbapenem-resistant enterobacterales infections: A retrospective cohort study
by: Nada Alhamed, et al.
Published: (2025-07-01)

A Tentative Clinical Study: Colistin Combined with Ceftazidime/Avibactam in the Treatment of Carbapenem-Resistant Gram-Negative Bacilli Infection
by: Zhang R, et al.
Published: (2025-08-01)

Impact of ceftazidime avibactam on colonization by carbapenem resistant Enterobacterales during treatment of related infections
by: Uğur Önal, et al.
Published: (2025-08-01)

The Impact Of Ceftazidime-Avibactam Utilization In Hospital Setting
by: Shobana Selvaganesan, et al.
Published: (2024-12-01)

Ceftazidim-avibactam susceptibility of carbapenemase producing enterobacterales in an OXA-48 endemic area
by: Şevval Arduç Tok, et al.
Published: (2024-12-01)

Antibacterial Activity of Ceftazidime-avibactam against carbapenem-resistant non-fermenters Gram-negative bacteria: a cross-sectional study from a tertiary care hospital
by: Dr Farhan Rasheed
Published: (2025-03-01)

Assessment of in vitro activity of ceftazidime/avibactam on carbapenemase‐producing Enterobacterales from Iran: An experimental study
by: Mehri Haeili, et al.
Published: (2024-08-01)

Emergence of Tigecycline-Nonsusceptible Carbapenem-Resistant <i>Klebsiella pneumoniae</i> with Metallo-β-Lactamase and Transferable Ceftazidime-Avibactam Resistance in China
by: Yajuan Ni, et al.
Published: (2025-03-01)

Carbapenem-resistant Klebsiella pneumoniae infections in Chinese children: in vitro activities of ceftazidime-avibactam and aztreonam-avibactam against carbapenemase-producing strains in a two-center study
by: Xia Ran, et al.
Published: (2025-03-01)

Risk factors for mortality in patients treated with ceftazidime-avibactam for ceftazidime-avibactam susceptible carbapenem-resistant Klebsiella pneumoniae bacteremia
by: Yi-Tsung Lin, et al.
Published: (2025-09-01)

Investigating Gram-negative bacilli isolates’ sensitivity to ceftazidime/avibactam
by: Sunali, et al.
Published: (2025-01-01)

Efficacy, Safety, and Cost-Effectiveness Analysis of Ceftazidime-Avibactam versus Polymyxin B in the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections: A Target Trial Emulation
by: Na Hu, et al.
Published: (2025-05-01)

Ceftazidime–Avibactam Versus Polymyxin-Based Combination Therapies: A Study on 30-Day Mortality in Carbapenem-Resistant Enterobacterales Bloodstream Infections in an OXA-48-Endemic Region
by: Rıdvan Dumlu, et al.
Published: (2024-10-01)

Assessment of clinical effectiveness and safety of ceftazidime-avibactam in ‐treating multi-drug-resistant infections – A retrospective analysis at a tertiary care hospital in Saudi Arabia
by: Eman Merghani Ali, et al.
Published: (2025-09-01)

Economic evaluation of ceftazidime-avibactam vs. polymyxin B for treatment of hospital-acquired and ventilator-associated bacterial pneumonia
by: Jessica Matuoka, et al.
Published: (2025-07-01)

Assessment of in vitro antimicrobial activities of ceftolozane/tazobactam and ceftazidime/avibactam against carbapenem-resistant Pseudomonas aeruginosa clinical isolates
by: Dalia Salem, et al.
Published: (2025-04-01)

Treatment of pediatric central nervous system infection caused by carbapenem-resistant Klebsiella pneumoniae with ceftazidime/avibactam, two cases report and literature review
by: Lu Qing, et al.
Published: (2025-02-01)

Ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae accompanied hypermucoviscosity acquisition
by: Yingyi Guo, et al.
Published: (2024-10-01)

In vitro activity of aztreonam–avibactam combination against blood culture isolates of Stenotrophomonas maltophilia in Japan before the launch of ceftazidime–avibactam
by: Wataru Aoki, et al.
Published: (2025-05-01)

The efficacy and safety of ceftazidime/avibactam or polymyxin B based regimens for carbapenem-resistant Pseudomonas aeruginosa infection: a multicenter real-world and propensity score-matched study
by: Wen-Ming Long, et al.
Published: (2025-03-01)

Clinical Characteristics of Patients Who Acquired Gram-Negative Bacteria During Ceftazidime-Avibactam Therapy
by: Chien Chuang, et al.
Published: (2025-04-01)

Safety and Efficacy of Ceftazidime/Avibactam in the Treatment of Severe Neonatal Infections
by: Mi Zhou, et al.
Published: (2024-12-01)

Ceftazidime-Avibactam Versus Colistin for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infections: A Multicenter Cohort Study
by: Thamer A. Almangour, et al.
Published: (2025-01-01)

Ceftazidime–avibactam for the Treatment of Intra-abdominal Sepsis and Urosepsis: A Retrospective Hospital-based Study in India
by: Prachee Sathe, et al.
Published: (2024-12-01)

Current treatment options for infections caused by carbapenem-resistant Enterobacteriaceae in patients with hematological malignancies
by: G. A. Klyasova
Published: (2020-07-01)

Study on the invitro synergistic susceptibility and biofilm inhibition mechanism of ceftazidime-avibactam combined with aztreonam against carbapenem-resistant Klebsiella pneumoniae
by: Guangfen Wang, et al.
Published: (2025-03-01)

Investigation of EDTA-carbaNP-direct test for the detection of metallobetalactamases in Pseudomonas aeruginosa
by: Hanife Tutan, et al.
Published: (2024-12-01)

Genomic epidemiology and ceftazidime-avibactam high-level resistance mechanisms of Pseudomonas aeruginosa in China from 2010 to 2022
by: Xi Li, et al.
Published: (2024-12-01)

Multi-omics profiling of cross-resistance between ceftazidime-avibactam and meropenem identifies common and strain-specific mechanisms in Pseudomonas aeruginosa clinical isolates
by: Bartosz J. Bartmanski, et al.
Published: (2025-07-01)

Overexpression of blaSHV-12 caused by tandem amplification contributed to ceftazidime/avibactam resistance in hypervirulent and carbapenem-resistant Klebsiella pneumoniae
by: Chao Liu, et al.
Published: (2024-12-01)

Molecular mechanisms responsible KPC-135-mediated resistance to ceftazidime-avibactam in ST11-K47 hypervirulent Klebsiella pneumoniae
by: Qingyu Shi, et al.
Published: (2024-12-01)

Experience in Ceftazidime-Avibactam for treatment of MDR BGN infection in Oncologic Children
by: Wilson Toyohiro Hoshino, et al.
Published: (2025-03-01)

A Multicenter Retrospective Study on Real-World Outcomes of ceftazidime-avibactam in gram-negative bacterial infection in Taiwan
by: Tsung Ying Zegma Yang, et al.
Published: (2024-12-01)